All News
"Don't You Know Who I am?" (5.17.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
Read ArticleInfectious Mortality in Autoimmune Rheumatic Disorders
Infectious conditions are a significant cause of mortality in autoimmune rheumatic diseases (ARD). Among patients hospitalized with an infection, we compared in-hospital and long-term (3-year) mortality between those with and without ARD.
Interferons and Lupus Subsets
In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans.
Read ArticleRECIPE Study: Non-opioid Analgesics following Total Hip Arthroplasty
Patients undergoing total hip arthroplasty using a combination of paracetamol, ibuprofen, and dexamethasone, had optimal responses with the lowest morphine consumption, and fewer adverse events.
Read ArticleDoes Good Sleep Prevent Osteoporosis
As part of the University of Colorado Department of Medicine’s annual Research Day, held on April 23, faculty member Christine Swanson, MD, MCR, described her National Institutes of Health-funded clinical research on whether adequate sleep can help prevent osteoporosis.
Read ArticleMultiplicative Adverse Effects of Social Determinants of Health in Lupus Nephritis: A Meta-analysis and Systematic Review
A metanalysis shows that social determinants of health adversely impacts patients with lupus nephritis. Lupus nephritis is a significant complication of SLE, often with dramatic increases in morbid and mortal risks. Outcomes are likely to be augmented by social determinants of health, including socio-economic status, and social risk factors.
Read ArticleMethotrexate Does Not Increase ILD Risk in Dermatomyositis
A cohort analysis of dermatomyositis (DM) patients starting immunomodulators finds that methotrexate use was not associated with an increased risk of interstitial lung disease (ILD).
Read ArticleComplex Autoantibody Patterns in RA
Patients with rheumatoid arthritis (RA) all have a unique and diverse set of antibodies that are involved in the development of the disease.
Read ArticleSystemic Inflammation and Mortality in RA-ILD
Analysis of the German RABBIT registry shows that systemic inflammation, more so than disease activity, strongly influences all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD).
Read ArticleBiomarker Predictors of Osteoarthritis
Science Advances has reported that Duke University researchers have validated a biomarkers of osteoarthritis that may be identified 2 years before the appearance of radiographic OA.
Read ArticleARCTIC Rewind: Can You Taper DMARDs with Remission?
In an open-label, randomized, non-inferiority trial, rheumatoid arthritis patients in remission were subject to tapering of disease-modifying antirheumatic drugs (DMARDs), and while maintenance of remission was seen in some, many DMARD tapering patients did flare and were unable to maintain flare-free survival compared to those on stable conventional synthetic DMARDs.
Read ArticleTLR Antagonist in Lupus
An investigational Toll-like receptor (TLR) antagonist was effective in reducing biomarkers and clinical symptoms of systemic lupus erythematosus (SLE) in a pilot trial, evidence that the innate immune system may hold the key to lupus pathophysiology.
Read ArticleRheum Chapter Notes (4.26.2024)
Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.
Read ArticlePredicting Infection in Lupus Nephritis
Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN.
Read ArticlePredicting CKD Outcomes in Lupus Nephritis
An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.
A multicentre observational study of patients with biopsy-proven LN; either proliferative (PLN) or membranous (MLN) lupus nephritis were compared regarding clinical and laboratory presentation and long-term outcomes. The primary outcome was progression to chronic kidney disease (CKD).
Canary in a Coal Mine (4.19.2024)
Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.
Read ArticleSGLT2 Inhibitors Lowers Gout Risks in Type 2 Diabetes
A population-based cohort has demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) use in gout patients is superior to sulfonylurea therapy in lowering the risk of incident gout and recurrent flares among patients with type 2 diabetes (T2D).
Read ArticleRA-ILD at Higher Risk for Serious Infection and Death
A prospective, multicenter study from Spain has demonstrated higher rates of mortality and serious infection in rheumatoid arthritis–associated interstitial lung disease (RA-ILD) patients.
Read ArticleBiopsy Results in Sjogren's Syndrome
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected Sjogren's syndrome (SjD).
Burnout or Retire (4.12.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Is it time to worry about burnout and those who are leaving healthcare?
Read Article